A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants

Linglei Jiang, Tom A.P. Driedonks, Wouter S.P. Jong, Santosh Dhakal, H. Bart van den Berg van Saparoea, Ioannis Sitaras, Ruifeng Zhou, Christopher Caputo, Kirsten Littlefield, Maggie Lowman, Mengfei Chen, Gabriela Lima, Olesia Gololobova, Barbara Smith, Vasiliki Mahairaki, M. Riley Richardson, Kathleen R. Mulka, Andrew P. Lane, Sabra L. Klein, Andrew PekoszCory Brayton, Joseph L. Mankowski, Joen Luirink, Jason S. Villano, Kenneth W. Witwer

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Medicine and Dentistry